What question did this study set out to answer?

This study examines the real-world effectiveness, safety, and treatment persistence of upadacitinib in Crohn's disease patients.

May 2, 2026

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.

View Full Paper

Ask AI

Bookmark

This study examines the real-world effectiveness, safety, and treatment persistence of upadacitinib in Crohn's disease patients.
Multicenter observational study using data from the Eneida registry
Included 300 patients with Crohn's disease receiving upadacitinib
Disease activity assessed at baseline and weeks 12, 24, and 52
60%-62% of patients achieved corticosteroid-free clinical remission at weeks 12, 24, and 52
C-reactive protein normalization improved from 64% at week 12 to 74% at week 52
24% of patients reported adverse events, and 39% discontinued treatment

No takes yet. Share an insight, caveat, or question.

Multicenter observational study evaluates Upadacitinib's effectiveness and safety in Crohn's disease, suggesting meaningful clinical utility.

Iborra et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Multicenter observational study evaluates Upadacitinib's effectiveness and safety in Crohn's disease, suggesting meaningful clinical utility.